{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Hematology parameters that were planned for analysis were as follows: WBC count , neutrophil count , hemoglobin , hemocrit , platelet count , and lymphocytes. This analysis was planned but not performed for Part C as the study was terminated early during Part B.","groups":[{"description":"Participants were planned to receive repeat dosing of GSK3039294 at the predicted optimal clinical dose determined from Part B for a total of 21 days.","id":"OG000","title":"Part C: GSK3039294"}],"populationDescription":"Safety Population. Data was not collected as study was terminated due to safety reasons during conduct of Part B (end of Cohort 3) whereas Part C was not initiated.","reportingStatus":"POSTED","timeFrame":"Up to Day 63","title":"Part C: Number of Participants With Emergent Hematology Parameters by PCI Criteria","type":"PRIMARY"}